Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026.

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026. CEO David Weinstein described the company’s proprietary AI platform for accelerating therapeutic discovery in CNS disorders and strengthening biodefense preparedness.

The platform integrates multimodal biological datasets, advanced machine learning, and in vivo validation to identify targets, optimize candidates, and compress development timelines. The company said it is advancing discussions with pharmaceutical firms and government agencies about its biotech and biodefense capabilities.

Argus Feb 13 session

-10.21% close to close Open Argus

Details

News Market Reaction – LNAI

On Feb 13, the day this news came out, LNAI closed 10.21% below the previous close.

Data tracked by StockTitan Argus for the Feb 13 session.

Key Figures

AUD patients: ~30 million individuals Untreated AUD share: ~95% AUD economic cost: ~$250 billion +5 more

AUD patients

~30 million individuals

Estimated U.S. population affected by Alcohol Use Disorder

Untreated AUD share

~95%

AUD-affected individuals receiving no effective pharmacologic treatment

AUD economic cost

~$250 billion

Annual U.S. economic cost related to Alcohol Use Disorder

AI-drug revenue tailwind

$240 billion

Estimated revenue-at-risk tailwind cited for AI drug discovery deals

External innovation capital

~$1.3 trillion

Capital pool cited for external innovation in AI-enabled drug discovery

Shares sold short

~11 million shares

Short position vs post-split float of ~23 million shares

AChE model AUROC

0.94 AUROC

Performance of AI model distinguishing active AChE inhibitors

Alzheimer’s diagnostic lift

35% improvement

Improvement in diagnostic accuracy vs MRI alone in Alzheimer’s program

Previous AI Reports

4 past events · Latest: Jan 27

Same Type 4 events

1. Jan 27

   AI safeguard launch

   24h Move

   -2.0%

   Launch of Sentinel AI safeguard to block generation of novel chemical threats.

2. Jan 26

   AI AUD program

   24h Move

   -2.5%

   NIH-backed AI program expanded into commercial Alcohol Use Disorder drug discovery.

3. Oct 30

   AI neurotoxicity data

   24h Move

   -2.0%

   AI platform results for detecting acetylcholinesterase-targeting neurotoxic compounds.

4. Oct 06

   AI Alzheimer’s launch

   24h Move

   -1.6%

   Launch of AI-powered Alzheimer’s program with improved diagnostic accuracy claims.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biodefense, machine learning, in vivo

3 terms

biodefense medical

"an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute."

Biodefense is the set of tools, technologies and services designed to detect, prevent or respond to biological threats such as infectious diseases, engineered pathogens or accidental releases. For investors it signals a market focused on diagnostics, vaccines, protective gear, and rapid response systems — similar to an alarm-and-firefighting network for biological risks — which can drive revenue growth, government contracts and regulatory scrutiny depending on outbreak risks and public policy priorities.

machine learning technical

"integrates multimodal biological datasets, advanced machine learning, and in vivo validation"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

in vivo medical

"advanced machine learning, and in vivo validation systems to rapidly identify novel targets"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness.

"We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently."

During the national segment, Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across complex neurological disorders and emerging chemical and biological threat countermeasures.

The CNBC appearance underscores growing investor attention on scalable AI platforms transforming central nervous system therapeutics and national security–focused biodefense innovation. Highlights of the interview aired on Business Minute can be watched via the following link:

https://www.linkedin.com/posts/lunai-bioworks_were-proud-to-share-that-our-client-lunai-activity-7427770187589877760-hp3X

Lunai is actively advancing discussions with leading pharmaceutical companies and government agencies around both their biotech and biodefense capabilities.

About Lunai Bioworks
Lunai Bioworks (NASDAQ: LNAI) is an AI-powered biotech and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats. For more information, visit https://lunaibioworks.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding potential clinical impact, therapeutic benefit, development timelines, partnering strategy, and commercial value. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Lunai Bioworks undertakes no obligation to update forward-looking statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-highlights-drug-discovery-and-biodefense-ai-platform-on-cnbc-302687672.html

SOURCE Lunai Bioworks Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lunai Bioworks (LNAI) announce on CNBC on Feb 13, 2026?

They highlighted use of a proprietary AI platform to accelerate CNS drug discovery and biodefense programs. According to the company, CEO David Weinstein explained multimodal data, machine learning, and in vivo validation are used to speed target ID and candidate optimization.

How does Lunai Bioworks (LNAI) say its AI platform speeds drug discovery?

It speeds discovery by integrating multimodal biological datasets with advanced machine learning and in vivo validation. According to the company, this combination aims to identify novel targets, optimize candidates, and compress development timelines across complex neurological disorders.

What biodefense capabilities did Lunai Bioworks (LNAI) describe on CNBC?

They described AI-driven countermeasure discovery for emerging chemical and biological threats. According to the company, the platform is applied to biodefense preparedness by rapidly identifying targets and advancing threat-specific therapeutics and validations.

Is Lunai Bioworks (LNAI) partnering with pharma or government after the CNBC appearance?

The company said it is actively advancing discussions with leading pharmaceutical companies and government agencies. According to the company, those talks concern both its biotech therapeutic work and national security–focused biodefense capabilities.

Who spoke for Lunai Bioworks (LNAI) on CNBC and what was emphasized?

CEO David Weinstein spoke and emphasized deploying AI to accelerate CNS discovery and biodefense preparedness. According to the company, he highlighted precision biology, reduced development risk, and scaling high-impact therapeutic programs more efficiently.